Literature DB >> 24507168

Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy.

Apurva O Badheka1, Neeraj Shah2, Peeyush M Grover3, Nileshkumar J Patel2, Ankit Chothani4, Kathan Mehta5, Vikas Singh3, Abhishek Deshmukh6, Ghanshyambhai T Savani3, Ankit Rathod7, Sidakpal S Panaich1, Nilay Patel1, Shilpkumar Arora1, Vipulkumar Bhalara1, James O Coffey3, Raul D Mitrani3, Jonathan L Halperin8, Juan F Viles-Gonzalez9.   

Abstract

Although left ventricular (LV) hypertrophy has been proposed as a factor predisposing to atrial fibrillation (AF), its relevance to prognosis and selection of therapeutic strategies is unclear. We identified 2,105 patients with echocardiographic data on LV mass enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial. LV hypertrophy was defined as increased LV mass, stratified by American Society of Echocardiography criteria. The primary end point was all-cause mortality, secondary end point was as per AFFIRM trial definition, and tertiary end point was cardiovascular hospitalizations. We compared "strict" versus "lenient" rate control in patients with increased LV mass, and studied association of heart failure (HF) with preserved and decreased systolic function in patients with increased LV mass. Over 6 years, 332 deaths (15.7%) were reported. Adjusted hazard ratio (HR) of severely increased LV mass for all-cause mortality was 1.34 (95% confidence interval [CI] 1.01 to 1.79, p=0.045) for the overall population and 1.61 (95% CI 1.09 to 2.37, p=0.016) for the rhythm-control arm. Increased LV mass was a predictor of cardiovascular hospitalizations in the lenient rate-control group (HR 1.72, 95% CI 1.05 to 2.82, p=0.03) but not in the strict rate-control group. Severely increased LV mass was predictive of cardiovascular hospitalizations in patients with HF with preserved (HR 1.8, 95% CI 1.0 to 3.2, p=0.03) and decreased LV systolic function (HR 2.4, 95% CI 1.1 to 5.2, p=0.02). Thus, LV hypertrophy is a significant independent predictor of mortality in patients with AF, especially those managed with rhythm control. In patients with LV hypertrophy, strict rate control may be associated with better outcomes than lenient rate control. LV hypertrophy portends higher cardiovascular morbidity in patients with AF and HF.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24507168     DOI: 10.1016/j.amjcard.2013.12.021

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation.

Authors:  Song-Nan Li; Lu Wang; Jian-Zeng Dong; Rong-Hui Yu; De-Yong Long; Ri-Bo Tang; Cai-Hua Sang; Chen-Xi Jiang; Nian Liu; Rong Bai; Xin Du; Chang-Sheng Ma
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

2.  Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the  RE - LY Trial.

Authors:  Ziad Hijazi; Paolo Verdecchia; Jonas Oldgren; Ulrika Andersson; Gianpaolo Reboldi; Giuseppe Di Pasquale; Giovanni Mazzotta; Fabio Angeli; John W Eikelboom; Michael D Ezekowitz; Stuart J Connolly; Salim Yusuf; Lars Wallentin
Journal:  J Am Heart Assoc       Date:  2019-01-22       Impact factor: 5.501

3.  Anemia as an Independent Predictor of Adverse Cardiac Outcomes in Patients with Atrial Fibrillation.

Authors:  Wen-Hsien Lee; Po-Chao Hsu; Chun-Yuan Chu; Hung-Hao Lee; Meng-Kuang Lee; Chee-Siong Lee; Hsueh-Wei Yen; Tsung-Hsien Lin; Wen-Chol Voon; Wen-Ter Lai; Sheng-Hsiung Sheu; Ho-Ming Su
Journal:  Int J Med Sci       Date:  2015-07-16       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.